
Neglected Tropical Disease Treatment Market Report 2026
Global Outlook – By Drug Class (Anti-Parasite, Antifungal, Antibiotics, Other Drugs Class), By Disease Type (Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease, African Trypanosomiasis, Other Disease Types), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By End User (Hospital, Specialty Clinics, Homecare Settings, Other End Users) - Market Size, Trends, And Global Forecast 2026-2035
Neglected Tropical Disease Treatment Market Overview
• Neglected Tropical Disease Treatment market size has reached to $3.57 billion in 2025 • Expected to grow to $4.79 billion in 2030 at a compound annual growth rate (CAGR) of 6% • Growth Driver: Rising Prevalence Of Infectious Diseases Fueling The Growth Of The Market Due To Increasing Global Travel And Disease Spread • Market Trend: Innovative Treatments Driving Progress In Neglected Diseases • Asia-Pacific was the largest region in 2025.What Is Covered Under Neglected Tropical Disease Treatment Market?
Neglected tropical disease (NTD) treatment refers to medical interventions aimed at controlling, eliminating, or eradicating a group of infectious diseases that primarily affect impoverished populations in tropical and subtropical regions. The main goal of the treatment is to reduce disease burden, prevent disability, and improve the quality of life in affected communities. The main drug classes used in the treatment of neglected tropical diseases include anti-parasitic agents, antifungals, antibiotics, and others. Anti-parasite refers to any substance or treatment designed to prevent, kill, or eliminate parasitic organisms that infect humans, animals, or plants. These treatments target various disease types, including leishmaniasis, schistosomiasis, lymphatic filariasis, Chagas disease, African trypanosomiasis, and others. The medications are administered via two main routes, oral and parenteral, and are distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies. These treatments serve a wide range of end users, including hospitals, specialty clinics, homecare settings, and others.
What Is The Neglected Tropical Disease Treatment Market Size and Share 2026?
The neglected tropical disease treatment market size has grown strongly in recent years. It will grow from $3.57 billion in 2025 to $3.8 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to long-standing disease prevalence in tropical regions, support from global health organizations, expansion of donor-funded treatment programs, availability of generic therapeutics, increased public health awareness initiatives.What Is The Neglected Tropical Disease Treatment Market Growth Forecast?
The neglected tropical disease treatment market size is expected to see strong growth in the next few years. It will grow to $4.79 billion in 2030 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to increasing investments in eradication programs, rising adoption of integrated disease management approaches, expansion of novel antiparasitic drug development, growing public-private partnerships, increasing focus on healthcare access in remote regions. Major trends in the forecast period include increasing deployment of combination drug therapies, rising focus on early disease detection programs, growing use of mass drug administration strategies, expansion of community-based treatment models, enhanced emphasis on treatment accessibility.Global Neglected Tropical Disease Treatment Market Segmentation
1) By Drug Class: Anti-Parasite, Antifungal, Antibiotics, Other Drugs Class 2) By Disease Type: Leishmaniasis, Schistosomiasis, Lymphatic Filariasis, Chagas Disease, African Trypanosomiasis, Other Disease Types 3) By Route of Administration: Oral, Parenteral 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 5) By End User: Hospital, Specialty Clinics, Homecare Settings, Other End Users Subsegments: 1) By Anti-Parasite: Anthelmintics, Antiprotozoals, Antimalarials, Ectoparasiticides 2) By Antifungal: Azoles, Polyenes, Allylamines, Echinocandins 3) By Antibiotics: Tetracyclines, Macrolides, Rifamycins, Sulfonamides 4) By Other Drug Classes: Antivirals, Corticosteroids, Combination Therapies, Supportive TreatmentsWhat Is The Driver Of The Neglected Tropical Disease Treatment Market?
The rising prevalence of infectious diseases is expected to propel the growth of the neglected tropical disease treatment market going forward. Infectious diseases refer to illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can spread directly or indirectly from one person to another. The rising prevalence of infectious diseases is due to increasing travel, which facilitates the rapid spread of pathogens across borders. Neglected tropical disease treatment aids infectious diseases by providing targeted therapies that control and eliminate disease spread. These treatments improve public health outcomes, especially in vulnerable communities, by reducing disease burden and preventing long-term disabilities. For instance, in February 2024, according to the UK Health Security Agency, a UK-based government agency, tuberculosis cases in England rose to 4,850 in 2023, an increase of 10.7% from 4,380 cases in 2022. Therefore, the rising prevalence of infectious diseases is driving the growth of the neglected tropical disease treatment industry.Key Players In The Global Neglected Tropical Disease Treatment Market
Major companies operating in the neglected tropical disease treatment market are Pfizer Inc, Johnson And Johnson, Merck And Co Inc, AbbVie Inc, Bayer AG, Novartis AG, Sanofi SA, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc, Eisai Co Ltd, Shionogi And Co Ltd, Dr Reddys Laboratories Ltd, Cipla Ltd, Gilead Sciences Inc, Bristol Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Lupin Limited, AlvogenGlobal Neglected Tropical Disease Treatment Market Trends and Insights
Major companies operating in the neglected tropical disease treatment market are focusing on developing innovative solutions, such as all-oral, field-deployable therapeutics, to simplify administration, improve safety, and expand access in low-resource settings. All-oral therapeutics for diseases like human African trypanosomiasis involve small-molecule drugs administered orally over a short course, which helps improve treatment reach, reduce the need for hospitalization, and lower operational barriers compared with traditional injectable therapies. For instance, in December 2023, Sanofi S.A., a France-based multinational pharmaceutical company, introduced Fexinidazole Winthrop, an oral treatment developed in partnership with not-for-profit organizations. Fexinidazole is a nitro-containing small molecule designed to replace older regimens requiring intravenous delivery or hospitalization. Its oral formulation, simplified dosing schedule, and favourable safety profile make it suitable for use across both stages of certain forms of sleeping sickness, expanding treatment access in remote settings. Furthermore, Fexinidazole contrasts with traditional alternatives such as melarsoprol and eflornithine, which are injectable, require complex monitoring, and have higher toxicity or operational challenges.What Are Latest Mergers And Acquisitions In The Neglected Tropical Disease Treatment Market?
The expansion of healthcare infrastructure is expected to propel the growth of the neglected tropical disease treatment market going forward. Healthcare infrastructure refers to the facilities, equipment, systems, and workforce needed to deliver effective medical care to a population. The rise in healthcare infrastructure is driven by population growth, as expanding communities require more hospitals, clinics, and medical facilities to meet increasing healthcare demand. Medical antibacterial curtains help healthcare infrastructure by reducing the spread of infections, creating safer patient environments, and supporting hospitals in maintaining higher hygiene standards. For instance, in 2024, according to the American Hospital Association, a US-based non-profit organization, the United States had a total of 6,120 hospitals in 2024, marking an increase from 6,093 hospitals in 2022. Therefore, the expansion of healthcare infrastructure is driving the growth of the neglected tropical disease treatment market.Regional Outlook
Asia-Pacific was the largest region in the neglected tropical disease treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.What Defines the Neglected Tropical Disease Treatment Market?
The neglected tropical disease treatment market consists of revenues earned by entities by providing services such as mass drug administration, disease surveillance, diagnostic testing, patient care and management, health education, and vector control programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The neglected tropical disease (NTD) treatment market also includes sales of diagnostic kits, vaccines, insecticides, and medical devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.What Key Data and Analysis Are Included in the Neglected Tropical Disease Treatment Market Report 2026?
The neglected tropical disease treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neglected tropical disease treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Neglected Tropical Disease Treatment Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $3.8 billion |
| Revenue Forecast In 2035 | $4.79 billion |
| Growth Rate | CAGR of 6.3% from 2026 to 2035 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 - 2035 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2035 |
| Segments Covered | Drug Class, Disease Type, Route of Administration, Distribution Channel, End User |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, ... |
| Key Companies Profiled | Pfizer Inc, Johnson And Johnson, Merck And Co Inc, AbbVie Inc, Bayer AG, Novartis AG, Sanofi SA, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc, Eisai Co Ltd, Shionogi And Co Ltd, Dr Reddys Laboratories Ltd, Cipla Ltd, Gilead Sciences Inc, Bristol Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Lupin Limited, Alvogen |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
